Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Gets CE Mark for Lung Cancer CDx

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics announced yesterday that it has secured CE marking for its HTG EdgeSeq ALKPlus assay EU, clearing the test for sale in the European Union.

The in vitro diagnostic runs on HTG's EdgeSeq next-generation sequencing system and is designed to measure and analyze mRNA ALK gene rearrangements in lung tumor specimens from patients previously diagnosed with non-small cell lung cancer. It can be used to identify patients suitable for treatment with ALK-targeted therapeutics such as Pfizer's Xalkori (crizotinib).

"We are pleased to add the HTG EdgeSeq ALKPlus assay EU to our diagnostic assay menu in Europe," HTG President and CEO T.J. Johnson said in a statement. "We plan to offer this assay to selected European early adopters as we seek additional regulatory approvals elsewhere."

In January, HTG announced that it had submitted the third of four expected modules for the assay's premarket approval application to the US Food and Drug Administration. The fourth module is expected to be completed this year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.